Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemotherapy
© 2024. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd..
PURPOSE: The transmembrane serine protease 4 (TMPRSS4) gene is upregulated in various human cancers. However, its biological functions in pancreatic ductal adenocarcinoma remain unclear. We examined the expression of TMPRSS4 in pancreatic ductal adenocarcinoma tissues and its correlation with clinicopathological parameters in patients with pancreatic ductal adenocarcinoma who underwent surgery.
METHODS: The TMPRSS4 expression was immunohistochemically examined in 81 PDAC patients with pancreatic ductal adenocarcinoma. We analyzed the association between the TMPRSS4 expression and clinicopathological factors, the recurrence-free survival (RFS), and the overall survival (OS) and examined the effect of TMPRSS4 expression on cell migration and sensitivity to 5-fluorouracil.
RESULTS: The expression rate of TMPRSS4 in the samples was 62.9% (51/81). The TMPRSS4 expression was not correlated with any clinicopathological feature. The five-year overall and recurrence-free survival rates were significantly lower in the TMPRSS4-positive group than in the TMPRSS4-negative group. On a multivariate analysis, TMPRSS4 positivity, poorly differentiated histology, and non-adjuvant chemotherapy predicted a poor OS, while TMPRSS4 positivity and poorly differentiated histology predicted a poor RFS. TMPRSS4-silenced pancreatic ductal adenocarcinoma cells showed higher sensitivity to 5- fluorouracil than did the control siRNA-transfected cells.
CONCLUSIONS: TMPRSS4 can be considered a prognostic factor and therapeutic target for pancreatic ductal adenocarcinoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Surgery today - (2024) vom: 19. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tazuma, Sho [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5-Fluorouracil |
|---|
| Anmerkungen: |
Date Revised 18.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s00595-024-02824-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371263255 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371263255 | ||
| 003 | DE-627 | ||
| 005 | 20240419233308.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240419s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00595-024-02824-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM371263255 | ||
| 035 | |a (NLM)38637344 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tazuma, Sho |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemotherapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. | ||
| 520 | |a PURPOSE: The transmembrane serine protease 4 (TMPRSS4) gene is upregulated in various human cancers. However, its biological functions in pancreatic ductal adenocarcinoma remain unclear. We examined the expression of TMPRSS4 in pancreatic ductal adenocarcinoma tissues and its correlation with clinicopathological parameters in patients with pancreatic ductal adenocarcinoma who underwent surgery | ||
| 520 | |a METHODS: The TMPRSS4 expression was immunohistochemically examined in 81 PDAC patients with pancreatic ductal adenocarcinoma. We analyzed the association between the TMPRSS4 expression and clinicopathological factors, the recurrence-free survival (RFS), and the overall survival (OS) and examined the effect of TMPRSS4 expression on cell migration and sensitivity to 5-fluorouracil | ||
| 520 | |a RESULTS: The expression rate of TMPRSS4 in the samples was 62.9% (51/81). The TMPRSS4 expression was not correlated with any clinicopathological feature. The five-year overall and recurrence-free survival rates were significantly lower in the TMPRSS4-positive group than in the TMPRSS4-negative group. On a multivariate analysis, TMPRSS4 positivity, poorly differentiated histology, and non-adjuvant chemotherapy predicted a poor OS, while TMPRSS4 positivity and poorly differentiated histology predicted a poor RFS. TMPRSS4-silenced pancreatic ductal adenocarcinoma cells showed higher sensitivity to 5- fluorouracil than did the control siRNA-transfected cells | ||
| 520 | |a CONCLUSIONS: TMPRSS4 can be considered a prognostic factor and therapeutic target for pancreatic ductal adenocarcinoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5-Fluorouracil | |
| 650 | 4 | |a Pancreatic ductal adenocarcinoma | |
| 650 | 4 | |a TMPRSS4 | |
| 650 | 4 | |a siRNA | |
| 700 | 1 | |a Sudo, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Shibata, Yoshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Kuraoka, Kazuya |e verfasserin |4 aut | |
| 700 | 1 | |a Uemura, Kenichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Tashiro, Hirotaka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Surgery today |d 1997 |g (2024) vom: 19. Apr. |w (DE-627)NLM012623938 |x 1436-2813 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:19 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00595-024-02824-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 19 |c 04 | ||